logo
#

Latest news with #Minogue

Update after Aussie icon Magda Szubanski revealed cancer battle
Update after Aussie icon Magda Szubanski revealed cancer battle

News.com.au

time15-07-2025

  • Entertainment
  • News.com.au

Update after Aussie icon Magda Szubanski revealed cancer battle

Beloved Aussie actor and comedian Magda Szubanski has given fans a rare update after revealing her heartbreaking cancer battle earlier this year. The 64-year-old confirmed the shocking diagnosis of stage-four Mantle Cell Lymphoma, a rare and fast-moving blood cancer, in a social media post on May 29. Szubanski described the cancer diagnosis as 'serious' and confirmed she had begun the 'the Nordic protocol' … 'one of the best treatments available' for the disease that was randomly picked up during a breast screening. In a clip posted to Instagram on Monday, the Kath and Kim alum could be seen wearing a grey hoodie and her head now fully bald from ongoing treatment. 'Having the cancer is not all bad because, look,' she smiled as she panned over to a gifted Lego set. 'I am such an 11-year-old boy trapped in a 64-year-old lesbian's body. I don't know how that happened, it just is what it is,' she continued. 'Getting so bored now,' she concluded. In the caption the comedian added the gift - a model Land Rover vehicle - will keep her busy for a bit. 'Tricky with chemo induced numbness in fingertips but … I've planned ahead and ordered a building kit with pliers and finger protectors,' she said. The video has received over 92,000 likes in just 15 hours, including from fellow stars Kylie and Dannii Minogue, Lisa Wilkinson and Rove McManus. In her clip earlier this year she assured fans she was being 'lovingly cared for by friends and family'. 'My medical team is brilliant and I've never felt more held by the people around me,' she said. 'I'll be lying very low while my immune system takes a hammering. 'This is an obscure cancer and was only diagnosed incidentally via a breast screen where they found my lymph nodes were up. 'To be honest, I've been feeling pretty ratshit for ages. So I asked for extra bloods and – voila! 'So the take away is – get tested and listen to your body! 'For now, just know I'm in good hands, good spirits – but I reserve my human right to be a cranky old moll,' she said. According to the Cancer Council, numbness in hands or feet is a common side effect of some types of chemotherapy drugs. The sensation is called peripheral neuropathy and may last a few months after treatment finishes or permanently.

Defeat to Scotland leaves Ireland U20s needing victory over Spain to avoid wooden spoon
Defeat to Scotland leaves Ireland U20s needing victory over Spain to avoid wooden spoon

Irish Examiner

time14-07-2025

  • Sport
  • Irish Examiner

Defeat to Scotland leaves Ireland U20s needing victory over Spain to avoid wooden spoon

World Rugby U20 Championship: Scotland 22 Ireland 21 Ireland will face Spain next Saturday bidding to avoid the wooden spoon for the first time ever at the World Rugby U20 Championship as their disastrous year at this grade took another big nosedive in northern Italy. Ireland, whose only win in the Six Nations this year was when they finished bottom came against Scotland, looked to have done enough when they came from ten points down in the final quarter to lead for the first time. And it seemed were going to hold on when Scotland were pinged for an offside as they came with a final onslaught — but the decision was reversed on review and the Scottish, who hadn't beaten Ireland in this grade for seven years, made the most of the reprieve for Glasgow Warriors academy hooker Jake Shearer to squeeze over while they had a second penalty advantage in the final play in Verona. Scotland will now play Georgia for ninth place while Neil Doak's side, who were World Championship semi-finalists last year and runners-up the previous season, need to beat Spain to avoid the ignominy of finishing bottom for the first time. Scotland, who had lost all three pool games including a 73-14 hammering by South Africa and a 56-19 drubbing from England, were good value for their 17-7 interval lead and would have been further ahead had they not had two tries scratched on review by the television match official. Ireland were on the back foot from the sixth minute when a strong run by Scottish left winger Fergus Watson set up a promising opportunity inside the 22 in front of the posts and they went wide for the other winger Nairn Moncrieff to score an unconverted try in the right corner. They doubled the lead four minutes later when hooker Seb Stewart, who made his Glasgow Warriors debut against Leinster at the end of the season, scored off a lineout drive after a good 50:22 from out-half Matthew Urwin. Oisín Minogue, who had scored in Ireland's last two games, got in for a try after a lineout take by Michael Foy but there was obstruction in the move and it was wiped. Minogue turned provider off another lineout and this time captain Henry Walker scored, with Sam Wisniewski's conversion cutting the gap to 10-7 after 26 minutes. Flanker Ollie Duncan, who played for Kilkenny RFC before his family returned to Edinburgh, scored after good work by scrum-half Hector Patterson and winger Watson with Urwin's conversion making it 17-7 after 29 minutes. Duncan then had a try disallowed for taking out Irish scrum-half Clark Logan as they raced for the line and moments later there was another let-off for Ireland when scrum-half Patterson grazed the touchline before touching down in the right corner. An eventful opening half for Duncan saw him binned for a dangerous tackle at the breakdown on Minogue and it remained yellow after a bunker review. Ireland failed to score while they had the extra man and they also failed to cut the deficit despite dominating the third quarter. But they got a lifeline when replacement hooker Liam McLaughlin — skipper Walker had to move to the back row as injuries mounted but he still did the lineout throws — got over from close range and Daniel Green converted to cut the gap to 17-14 after 65 minutes. And they hit the front for the first time when Eoghan Smyth put Paidí Farrell away down the right and the winger from Tullamore went outside Jed Finlay to score an excellent try in the corner, his third of the tournament. Green, now at out-half, landed a superb touchline conversion to make it 21-17. But Ireland were unable to hold and were duly punished by the Scots. Scorers for Scotland: Tries: N Moncrieff, S Stephen, O Duncan, J Shearer. Con: M Urwin. Scorers for Ireland: Tries: H Walker, L McLaughlin, P Farrell. Cons: D Green (2), S Wisniewski. IRELAND: D Green; P Farrell, C Mangan, E Smyth (J Scott 75), G O'Leary Kareem (C Molony 3-13 blood); S Wisniewski (Molony 60), C Logan (W Wootton 35); A Usanov (P Moore 35), H Walker, A Mullan (T McAllister 57); M Ronan (L McLaughlin 56), C Kennelly (B Corrigan 52); M Foy, B Power, O Minogue (D Walsh 52). SCOTLAND: J Brown; N Moncrieff (J Finlay 68), J Ventisei, K Yule, F Watson; M Urwin (J Hocking 79), H Patterson (N Cowan 73); O McKenna (B White 55), S Stephen (J Roberts 60), O Blyth-Lafferty (J Shearer 62); D Cockburn (C Moss 55), B Godsell; O Duncan, F Douglas, R Logan. Referee: Filippo Russo (Italy).

Nephew of late Munster great scores sensational try for Ireland U20s
Nephew of late Munster great scores sensational try for Ireland U20s

Extra.ie​

time10-07-2025

  • Sport
  • Extra.ie​

Nephew of late Munster great scores sensational try for Ireland U20s

It wasn't to be for the Ireland U20s in Italy as, despite racing to an early lead, the power and depth of the 'Baby Blacks' shone through and they ran riot, beating Ireland 69-22. It wasn't the result Neil Doak's side needed in their fight for the semi-finals, and it means that they are now in the ninth-place bracket in the World Rugby U20s Championships. There was plenty of hope heading into the game and those hopes were backed up when, after just six minutes, Ireland were already 12-0 up, with their first score coming in sensational fashion. Oisin Minogue scores a try Pic:Massimiliano Carnabuci/Sportsfile With just over a minute on the clock, Irish fly-half Tom Wood (son of Keith) slotted through a delicate grubber kick behind the Kiwi defence heading towards flanker and fellow Munster man Oisín Minogue. Minogue, a flanker by trade, then proceeded to pull off an immense piece of skill by flicking the ball over the New Zealand fullback before regathering it and scoring. Minogue comes from great Munster rugby stock. A Shannon RFC man, Minogue is the son of former Ireland International Rosie Foley and the nephew of former Munster captain and Head Coach, the late great Anthony 'Axel' Foley. Foley played over 200 times for Munster as well as earning 62 caps for Ireland as he was part of the famous Munster side that won two Heineken Cups in 2006 and 2008. He then took up coaching and was the Head Coach for Munster from 2014 until his untimely passing in 2016. Former Munster head coach Anthony Foley Pic: Brendan Moran / SPORTSFILE The fast start continued just minutes later when fullback Daniel Green was able to cross over after Minogue made another monstrous break through the Kiwi midfield as Ireland were now 12-0 up after just six minutes. However, that was as good as it got for Ireland as the Kiwis got back into their groove. They got their first try through number 8 Mosese Bason after just 10 minutes and the floodgates opened from there as it was already 31-15 at halftime to the Kiwis. With Ireland now chasing the game it was only going to go one of two ways, Ireland make a miraculous comeback or New Zealand run riot. The latter was to happen, unfortunately for Ireland, as the 'Baby Blacks' ran in six second half tries while Ireland's Billy Bohan received a red card for foul play. Sam Wisniewski dejected after the match Mandatory Credit ©INPHO/Sebastiano Pessina Ireland U20s weren't successful in reaching the semi-finals but that doesn't mean their tournament is over. They now go into the ninth-place bracket where they'll first face Scotland on Monday July 14 and, if they win, they'll face the winner of Georgia and Spain for ninth-place, which will go a long way for seeding in next year's Championship.

Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Business Wire

time09-07-2025

  • Business
  • Business Wire

Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company specializing in bariatric and obesity care. This new partnership draws upon Minogue Medical's 40-year experience in the Canadian market and reflects Allurion's commitment to establishing a new standard of care in obesity management focused on metabolically healthy weight loss. Minogue Medical has extensive experience in building high-performing medical networks across Canada. With a national ecosystem of dietitians, bariatric surgeons, and endoscopic specialists, the company ensures every patient journey is supported by highly qualified professionals who deliver a comprehensive program. Through its rigorous vetting and training processes, Minogue has become a trusted name in bringing advanced technologies into clinical practice. 'We select partners who share our vision for ethical, patient-centered care,' said Danny Minogue, CEO of Minogue Medical. 'Allurion's commitment to clinical rigor complements our approach, and together, we intend to set a new benchmark in Canadian weight management.' Allurion is pioneering metabolically healthy weight loss, a new approach to obesity care focused on losing weight, keeping it off, and maintaining muscle. In partnership with Minogue Medical, Allurion will now be able to access providers who are committed to this approach and have demonstrated exceptional clinical results. In addition, the partnership is expected to increase access to providers offering a combination of the Allurion Program with GLP-1 therapy, to further enhance short and long-term results. 'Minogue Medical has built a strong reputation in Canada for its deep clinical expertise, strong network, and a proven ability to bring meaningful innovations to the field of metabolic and bariatric care,' said Dr. Michel Gagner, a leading Canadian bariatric surgeon. 'Their multidisciplinary approach—engaging dietitians, surgeons, and endoscopists alike—ensures that patients are treated within a medically supervised, evidence-based framework. I am confident that this partnership represents a pivotal step forward for obesity care in Canada.' 'This agreement with Minogue Medical reflects our commitment to find partners globally who believe in our approach to obesity care,' said Dr. Shantanu Gaur, Founder and CEO of Allurion. 'We are looking forward to working with Minogue to develop the Canadian market and establish a new standard of care in the treatment of obesity.' About Minogue Medical Inc. Minogue Medical is a Canadian medical device distributor with deep expertise in the bariatric and metabolic health space. With a focus on ethical integration, clinician training, and long-term care pathways, Minogue supports a national network of medical professionals in delivering high-quality, patient-centered care. About Allurion Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, Procedureless TM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States. For more information about Allurion and the Allurion Virtual Care Suite, please visit Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world. Forward-Looking Statements This press release contains forward-looking statements that reflect Allurion's beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: establishing a new standard for weight loss; choosing appropriate partners; pioneering inability healthy weight loss; the uniqueness of Allurion's product and service offerings, including the Allurion Program; and other statements about future events that reflect the current beliefs and assumptions of Allurion's management based on information currently available to management. Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Program, including the Allurion Balloon; the timing of, and results from, Allurion's clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Balloon; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ('SEC') on March 27, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store